Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMR-687 in HFpEF
NCT05312021Phase 2Withdrawn
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in heart failure with preserved ejection fraction (HFpEF), sponsored by Cardurion Pharmaceuticals. Primary endpoint: Change in NT-proBNP at 16 weeks. Planned start Apr 2022; status: withdrawn.
02
Drugs
tovinontrine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05312021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312021.